CALGARY, ALBERTA--(Marketwire - May 28, 2008) - Stem Cell Therapeutics Corp. (“SCT”) (TSX VENTURE: SSS) is pleased to announce the enrollment of the first patient in its REGENESIS Phase IIb stroke trial. The REGENESIS trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for SCT’s lead program, NTx™-265, for the treatment of acute ischemic stroke. This first patient was enrolled by the clinical team of Judith Jarrett, Dr. Gordon Gubitz and Dr. Stephen Phillips at the Queen Elizabeth II Health Sciences Centre in Halifax, NS. Co-lead investigators for the REGENESIS Phase IIb trial are Dr. Steven C. Cramer, Principle Investigator of the BETAS Phase IIa stroke trial, at the University of California, Irvine; and Dr. Michael Hill at the Foothills Hospital at the University of Calgary.
